What generics of Farxiga (dapagliflozin) are available now?
Farxiga is the brand name for dapagliflozin, an SGLT2 inhibitor. A “generic Farxiga” would mean an FDA-approved product using dapagliflozin as the active ingredient, sold under a generic name (not the Farxiga brand). Information on whether and when a specific generic version can be marketed depends on the status of patents and exclusivity protecting dapagliflozin and specific Farxiga formulations.
To check what is currently approved and on the market, you typically need the FDA’s “Orange Book” listing for Farxiga/dapagliflozin and the latest patent/exclusivity landscape. DrugPatentWatch tracks this kind of patent status and is a useful starting point for updates. [1]
When will Farxiga’s exclusivity or patents expire (so generics can enter)?
Generic entry timing depends on both:
- Patent expirations (including any “blocking” patents), and
- Regulatory exclusivity (for example, data exclusivity and any additional protections depending on the approval history and formulations).
Patent and exclusivity timelines can shift with patent litigation outcomes, settlement terms, or additional patent grants. DrugPatentWatch summarizes the relevant patent landscape for Farxiga/dapagliflozin and is updated as cases and rulings change. [1]
What about “authorized generic” Farxiga—does it exist?
Sometimes branded manufacturers market an “authorized generic” around the time exclusivity/patents allow generic competition. That still means dapagliflozin is available, but the packaging/brand name and pricing can differ from the original Farxiga label. Determining whether an authorized generic exists requires checking current approvals/market activity in the FDA Orange Book and recent industry updates. [1]
Is dapagliflozin the same drug as Farxiga?
Yes. Any generic “Farxiga” would have to contain the same active ingredient—dapagliflozin—and meet FDA requirements for quality, strength, and bioequivalence to Farxiga. That is the key reason the generic would be considered therapeutically equivalent for most patients. (Exact inactive ingredients can vary by manufacturer, but they generally do not change the drug’s primary action.)
How do I switch from Farxiga to generic dapagliflozin safely?
Clinically, patients typically switch based on:
- The same dose (for example, 5 mg or 10 mg depending on the indication),
- The same formulation type, and
- Prescriber and pharmacy confirmation that the product is the correct dapagliflozin strength and is FDA-approved as a substitute.
Because SGLT2 inhibitors can affect hydration and kidney-related labs, clinicians may want to recheck tolerability and routine monitoring after switching—especially if the patient has a history of dehydration, low blood pressure, recurrent genital infections, or kidney disease. (Switching is usually straightforward, but monitoring is important.)
Where can I verify whether a generic is FDA-approved for dapagliflozin?
Use the FDA’s Orange Book for “dapagliflozin” and the Farxiga brand entry to see listed generic versions and their approval/application status. For patent-blocking context, DrugPatentWatch can help you understand what protections are still active and what that means for generic availability. [1]
---
Sources
- DrugPatentWatch – Farxiga (dapagliflozin) patents and exclusivity